PHIO - RXi Pharmaceuticals Qarzning balans kapitallashuviga nisbati

RXi Pharmaceuticals (PHIO) tovar belgisi

Nuklein kislotani yetkazib berish yo'nalishidagi yuqori raqobat Phio Pharmaceuticals (PHIO) moliyaviy holatiga salbiy ta'sir ko'rsatmoqda. GURU.Markets grafigidagi balans kapitali tuzilmasiga nisbatan qarz majburiyatlari joriy yukni aks ettiradi, bunda 0.00 qiymati metrika darajasini qayd etgan. Optimallashtirish INTASYL sinovlarining muvaffaqiyati, investitsiyalarni jalb qilish va saratonni davolash uchun o'ziga xos mustaqil yetkazib beruvchi RNA platformasini monetizatsiya qilish orqali amalga oshirilishi mumkin.

Phio Pharmaceuticals Corp. (PHIO): Qarzning sof aktivlarga nisbati 04.07.2022dan 28.10.2026gacha

phiopharma.com (PHIO) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi Phio Pharmaceuticals Corp.|PHIO - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati PHIO|PHIO - Biznesning to‘liq qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Phio Pharmaceuticals|PHIO - Kompaniyaning buxgalteriya qiymati|Bozor kapitallashuvining balans qiymatiga nisbati phiopharma.com|PHIO - Kompaniya aktivlarining umumiy hajmi
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning xususiy kapitalga nisbati Phio Pharmaceuticals|PHIO - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Phio Pharmaceuticals Corp.|PHIO - Jamlangan qarz majburiyatlari|Qarzning balans kapitallashuviga nisbati PHIO
Kompaniyaning jamlanma tahliliyoti:Phio Pharmaceuticals
Phio Pharmaceuticals Corp yetakchi tovari

Ushbu ko'rsatkich qarz majburiyatlarining kompaniyaning sof aktiv qiymatiga nisbatan ulushini o'lchaydi. Ko'rsatkichning ortishi qizib ketish va qarzlar qoplash uchun kapital yetishmasligi xavfidan signal beradi. Kapitalizatsiyaga nisbatan qarzning moliyaviy barqarorlik metriklari tahlili orqali investor kompaniyaning haqiqiy leverajini baholaydi. Phio Pharmaceuticals (PHIO) uchun RNA ishlanmalariga ESG standartlarini joriy qilishda me'yordagi leveraj muhim ahamiyatga ega bo'lib, bu haddan tashqari qarz yukisiz axloqiy tadqiqotlarni ta'minlaydi.

Phio Pharmaceuticals raqobatchilari

Balans kapitallashuviga qarzlar TEM (Tempus AI Inc)|qiagen.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Ionis|RGEN - Qarzlarning balans kapitallashuviga nisbati|Balans kapitallashuviga qarzlar Avidity RNA|CRISPR (CRSP) - Qarzning sof aktivlarga nisbati|WGS: Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar RARE|Beam Therapeutics - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Sarepta Therapeutics SRPT|Qarzning balans qiymatiga nisbati Twist Bio|10x - Qarzning sof aktivlarga nisbati|Qarzning balans kapitallashuviga nisbati Intellia Therapeutics|STOK - Qarzlarning balans kapitallashuviga nisbati|Balans kapitallashuviga qarzlar BioLife Solutions BLFS|Wave Life Sciences Ltd (WVE) - Qarzning sof aktivlarga nisbati|MAZE (Maze Tx) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar SION|Prime Medicine, Inc. (PRME) - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati TSHA (tayshagtx.com)|uniQure - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati MeiraGTx Holdings MGTX|Regenxbio - Balans kapitallashuviga qarzlar|SLDB - Balans kapitallashuviga qarzlar|OCGN (Ocugen, Inc.) - Balans kapitallashuviga qarzlar|pacb.com (PACB) - Qarzning balans qiymatiga nisbati|Balans kapitallashuviga qarzlar BNTC (Benitec Biopharma)|Balans qiymatiga qarzlar Design Therapeutics Inc (DSGN)|Qarzning balans qiymatiga nisbati RCKT|Balans kapitallashuviga qarzlar 4D Molecular Corp FDMT|Qarzning balans qiymatiga nisbati Lexeo Therapeutics, Inc. (LXEO)|Qarzning balans kapitaliga nisbati Korro Bio Inc. KRRO|Balans kapitallashuviga qarzlar EDIT (Editas Medicine)|SLN - Sof aktivlarga qarzlar|PRQR (proqr.com) - Balans kapitallashuviga qarzlar|Codexis (CDXS) - Qarzning balans qiymatiga nisbati|SGMO (Sangamo Therapeutics) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar NAUT|Qarzning balans kapitallashuviga nisbati Metagenomi (MGX)|Qarzning balans kapitallashuviga nisbati DTIL (Precision BioSciences Inc.)|Qarzning balans kapitallashuviga nisbati GBIO|Boundless Bio Inc - Sof aktivlarga qarzlar|Qarzning balans kapitallashuviga nisbati Exicure Corp|IMNN - Qarzlarning balans kapitallashuviga nisbati|Balans kapitallashuviga qarzlar mustangbio.com MBIO|TransCode Therapeutics, Inc. (RNAZ) - Qarzning sof aktivlarga nisbati|BNGO: Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar APDN|bluebird bio, Inc. - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar immunoprecise.com (IPA)|OMGA - Balans kapitallashuviga qarzlar|Singular Genomics Systems, Inc. - Qarzning balans qiymatiga nisbati|Regulus Therapeutics Inc (RGLS) - Qarzning balans kapitallashuviga nisbati|SYRS - Qarzning balans qiymatiga nisbati|TBIO: Balans kapitallashuviga qarzlar|TCON (traconpharma.com) - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Unity Biotechnology, Inc. UBX